Interpace Biosciences (IDXG) 10-K/A 2023 FY Annual report (amended)

Exhibit 31.4

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Christopher McCarthy, certify that:

1.	I have reviewed this Annual Report on Form 10-K/A for the year ended December 31, 2023 of Interpace Biosciences, Inc. (the “registrant”); and
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 26, 2024	/s/ Christopher McCarthy
	Chief Financial Officer
	(Principal Financial Officer)